SLC2A1 and Miyoshi myopathy: Given the metabolic consequences of some anti-cancer treatments, such as HK and GLUT1 downregulation by bortezomib, as described above, this may also be a mechanism for MM to alter its metabolism to gain drug resistance, and oxidative phosphorylation is therefore a potential area of metabolism to target to combat resistance.